Article

Green Synthesis of Platinum and Palladium Nanoparticles Using *Peganum harmala* L. Seed Alkaloids: Biological and Computational Studies

Sherif Ashraf Fahmy 1,2,*, Iten M. Fawzy 3, Basma M. Saleh 1,*, Marwa Y. Issa 4,*, Udo Bakowsky 5,*, and Hassan Mohamed El-Said Azzazy 1,*

1 Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC Avenue, P.O. Box 74, Cairo 11835, Egypt; sheriffahmy@aucegypt.edu (S.A.F.); basma.saleh@aucegypt.edu (B.M.S.)
2 School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, R5 New Garden City, New Capital AL109AB, Cairo 11835, Egypt
3 Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo 12311, Egypt; iten.mamdouh@fue.edu.eg
4 Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt; marwa.issa@pharma.cu.edu.eg
5 Department of Pharmacognosy and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany

*Correspondence: ubakowsky@aol.com (U.B.); hazzazy@aucegypt.edu (H.M.E.-S.A.); Tel.: +49-6421-28-25884 (U.B.); +2-02-2615-2559 (H.M.E.-S.A.); Fax: +2-02-2795-7565 (H.M.E.-S.A.)

Abstract: This study reports a facile and eco-friendly method for the green synthesis of platinum and palladium nanoparticles (Pt NPs and Pd NPs) using *Peganum harmala* seed alkaloid fraction. The ζ-potential of the synthesized Pt NPs, Pd NPs and Pt–Pd NPs were \(-11.2 \pm 0.5\) and \(-9.7 \pm 1.2\), and \(-12.7 \pm 2.1\) mV, respectively. Transmission electron microscopy (TEM) revealed the formation of spherical-shaped nanoparticles with smooth margins. The mean diameters of the synthesized Pt NPs, Pd NPs, and Pt–Pd NPs were determined using TEM analysis and were found to be 20.3 ± 1.9, 22.5 ± 5.7, and 33.5 ± 5.4 nm, respectively. The nanoparticles’ bioreduction was confirmed by ultraviolet–visible (UV–vis) spectroscopy, X-ray diffraction (XRD) and Fourier transform infrared (FTIR) spectroscopy, and their organic contents were determined by thermal gravimetric analysis (TGA). The Pt–Pd NPs mixture showed more pronounced antioxidant activity of 843.0 ± 60 µM Trollox equivalent (TE)/mg NPs compared to the individual Pt NPs (277.3 ± 13.5 µM TE/mg NPs) and Pd NPs (167.6 ± 4.8 µM TE/mg NPs). Furthermore, the Pt–Pd NPs exhibited significant cytotoxic activities against lung cancer (A549) and breast adenocarcinoma (MCF-7) cells, IC50 of 8.8 and 3.6 µg/mL, respectively; as compared to Pt NPs (IC50 of 10.9 and 6.7 µg/mL, respectively) and Pd NPs (IC50 of 31 and 10.8 µg/mL, respectively and compared to carboplatin (IC50 of 23 and 9.5 µg/mL, respectively). Moreover, molecular docking studies were conducted to explore the possible anticancer and antioxidant mechanisms of the biogenic nanoparticles. Pt NPs, Pd NPs, and their mixture showed inhibitory activity against cysteine proteinase, which supports their high antitumor activity, but moderate antioxidant activity. In conclusion, Pd-Pt NPs mixture prepared using harmala seed alkaloid fraction showed potential as effective antineoplastic agents.

Keywords: green synthesis; platinum nanoparticles; palladium nanoparticles; *Peganum harmala* seed alkaloid fraction; antioxidant; anticancer

1. Introduction

Recently, noble metals nanoparticles (NNPs), including platinum and palladium nanoparticles (Pt NPs and Pd NPs, respectively), have gained attention as promising tools in cancer therapy and biomedical applications [1–3]. Pt NPs and Pd NPs have a localized surface plasmon resonance that produces unique absorption bands in the ultraviolet–visible

---

nanomaterials 2021, 11, 965. https://doi.org/10.3390/nano11040965
https://www.mdpi.com/journal/nanomaterials
(UV–Vis) region compared to their bulk counterparts [4,5]. Both nanoparticles can readily be taken up by cancer cells and have been reported to exhibit anticancer and antioxidant activities [6–8]. One study reported the synthesis of spherical bimetallic Pt–Pd NPs (10–25 nm) using Dioscorea bulbifera. The produced bimetallic NPs demonstrated a significant antineoplastic activity (74%) against human cervical (HeLa) cancer cells compared to individual Pd NPs (33%) and Pt NPs (12.6%) [9].

Various chemical approaches have been used for fabrication of Pt NPs and Pd NPs, however, they commonly use harsh reagents and synthetic capping agents [4,5,10,11]. Thus, biological systems such as microorganisms, seaweeds, and plant extracts have been proposed for simple, safe, and cost-effective fabrication of NPs [4,5,12]. Plant extracts can be readily prepared and harbor many phytochemicals that could act as natural reductants to reduce platinum (IV) and palladium (II) ions [4,5,13–15]. Few studies reported the green synthesis of bimetallic NPs using plant extracts. For instance, spherical gold-palladium NPs (7 nm), were prepared employing Cacumen platycladi leaf extract [5]. Luo et al. reported a simple method for green synthesis of Fe–Pd NPs (10–100 nm) using grape leaf extract [5]. A recent study reported the utilization of Terminalia chebula aqueous fruit extract for the green synthesis of spherical Ag–Pd NPs with an average particle size of 20 nm zeta potential of $-14.4 \text{ mV}$. The bimetallic Ag–Pd NPs showed noticeable anticancer activity against A549 cancer cells with IC$_{50}$ of 48.45 µg/mL [5]. Proteins in plant extracts have different functional groups which coat and stabilize the synthesized NPs [16]. Most of the reported studies focused on the green synthesis of Au and Ag NPs while few studies addressed the green synthesis of Pt and Pd NPs [4,5].

Peganum harmala L., belonging to Zygophyllaceae family, grows naturally in uncultivated zones in the Middle East and North Africa [17]. The seed of P. harmala is enriched in therapeutically active alkaloids, including β-carboline and quinazoline alkaloids (such as harmine, harmane, harmol, harmaline, harmalol, and peganine), jointly known as harmala alkaloids [17]. Also, the seed of P. harmala contains oxygenated monoterpenes (such as eugenol), anthraquinones, flavonoids, and polysaccharides which are responsible for the bioreduction of different metal ions [17,18]. The seeds of P. harmala possess a broad spectrum of biological molecules which have antimicrobial, antioxidant, and anticancer activities [17,19]. Green synthesis of Ag, Au, and ZnO NPs employing different P. harmala extracts has been reported [20–22].

In this work, a facile and eco-friendly method was used for green synthesis of Pt NPs, Pd NPs, and Pt–Pd NPs utilizing the alkaloid-rich fraction of Peganum harmala seed extract. The greenly synthesized nanoparticles were investigated for cytotoxic and antioxidant activities. In silico molecular modeling studies were conducted to explore their possible modes of action as anticancer and antioxidant agents (Scheme 1).
Scheme 1. Schematic diagram summarizing the steps involved in the green synthesis of platinum and palladium nanoparticles (Pt NPs, Pd NPs), and Pt–Pd NPs.

2. Materials and Methods

2.1. Materials

2.1.1. Chemicals

Platinum (IV) chloride and palladium (II) acetate were obtained from BLD Pharmatech Co., Limited, Cincinnati, OH, USA. TPTZ (2,4,6-tripyridyl-s-triazine) and FeCl$_3$.6H$_2$O were purchased from Sigma Aldrich, St. Louis, MO, USA. Streptomycin, penicillin, fetal bovine serum, trichloroacetic acid (TCA), Dulbecco’s Modified Eagle’s Medium (DMEM) for sulforhodamine B (SRB) assay, and Tris(hydroxymethyl)aminomethane were purchased from Lonza, (Basel, Switzerland).

2.1.2. Plant Material

Dried mature seeds of *Peganum harmala* L. were obtained from the local Egyptian market. A voucher specimen was deposited (18.1.17) at the Department of Pharmacognosy Herbarium, Faculty of Pharmacy, Cairo University (Giza, Egypt).

2.2. Methods

2.2.1. Preparation of *P. harmala* Seed Alkaloid Fraction

*P. harmala* seeds were ground and then extracted by soaking overnight in 70% ethanol at room temperature. The ethanolic extract was filtered and evaporated under reduced pressure yielding a dark reddish-brown viscous residue which was dissolved in 5% HCl, filtered, and partitioned using dichloromethane. The aqueous layer was adjusted to pH 9 using NH$_4$OH and then fractionated with dichloromethane. The dichloromethane layer was washed with water and evaporated under reduced pressure at 40 °C, yielding a reddish-brown powder (*P. harmala* seed alkaloid fraction) which was stored at room temperature in dark glass bottles [17].
2.2.2. Green Synthesis of Platinum and Palladium Nanoparticles (Pt NPs and Pd NPs)

*P. harmala* seed alkaloid fraction powder (0.2 g) was dissolved in 10 mL deionized water by magnetic stirring at 80 °C for 90 min followed by centrifugation at 4 °C and 12,000 rpm for 5 min. The yellow-colored solution was then filtered through Whatman no. 40 filter paper. Ten mL of the solution were added to 90 mL of an aqueous solution containing 1 mM Pt (IV) chloride or 1 mM Pd (II) acetate followed by magnetic stirring for 24 h at 60 °C. Color change from yellow to dark brown indicated the formation of Pt NPs and Pd NPs. A mixture of Pt and Pd NPs was also prepared by adding 10 mL of the alkaloid solution to 90 mL of an aqueous solution containing 1 mM of both Pt (IV) chloride and Pd (II) acetate. The reaction conditions were the same as above. The prepared nanoparticles were collected by centrifugation (12,000 rpm) for 30 min at 4 °C. The pellet was washed with a mixture of ethanol and deionized water and then freeze-dried.

2.2.3. Characterization of Pt NPs and Pd NPs

UV–vis spectrophotometric tracking for the local surface Plasmon resonance (LSPR) of the greenly synthesized nanoparticles was conducted on a CARY 500 UV–vis–NIR Scan dual-beam spectrophotometer (Varian, Palo Alto, CA, USA). The $\zeta$-potential of the synthesized nanoparticles was studied using a laser Doppler velocimetry employing Zetasizer Nano ZS (Malvern Instruments Herrenberg, Germany) in a clear disposable folded capillary cell (DTS1070, Malvern Instruments).

The nanoparticles’ morphology and diameter size were examined using transmission electron microscopy (TEM) employing a JEOL-JEM 2100 electron microscope operating at 160 kV. A 50 µL aliquot of the nanoparticles was diluted in the ratio of 1:2 ($v/v$) with deionized water and stained with 2% aqueous phosphotungstic acid. This mixture was placed and dried over a carbon-coated copper 200 mesh grid, imagined, and photographed.

X-ray diffraction (XRD) analysis was performed to study the crystalline and elemental states of the prepared metallic nanoparticles. It was conducted in the range of 5° to 90° (each step is 0.03°, 1.5 s per step) at a generator voltage of 40 kV and current of 30 mA employing the Bruker D8 DISCOVER Family. The functional groups of *P. harmala* seed alkaloid fraction and the green synthesized Pt NPs, Pd NPs, and Pt–Pd NPs were identified using Fourier transform infrared (FTIR) spectroscopy performed on a FTIR-8400s (Shimadzu, Japan). Samples were first compressed with KBr into disks, scanned, and spectra recorded in the range of 500–4000 cm$^{-1}$. The thermal stability of the nanoparticles was studied using a Q50 TGA Thermogravimetric Analyzer, USA. The lyophilized powder was placed in the platinum pan and heated from 0 to 400 °C at a heating rate of 10 °C/min under a nitrogen atmosphere.

2.2.4. Total Antioxidant Activity

Standards and Samples Preparation

Ten serial dilutions (4000, 3000, 2000, 1000, 800, 600, 400, 200, 100, and 50 µM) of Trolox stock solution (positive control; 5 mM in methanol) were prepared. Pt NPs, Pd NPs, and Pt–Pd NPs were prepared at a concentration of 0.68 mg/mL methanol.

Ferric-Reducing Antioxidant Power (FRAP) Assay

The ferric-reducing antioxidant power (FRAP) assay relies on the antioxidant’s capability to reduce ferric ions into ferrous ions in the presence of TPTZ forming ferrous-TPTZ complex (intense blue color). The assay was conducted in microplates according to the method described by Benzi et al. with few modifications [23]. Briefly, 190 µL of TPTZ reagent were freshly prepared by mixing 300 mM acetate buffer (pH 3.6), 10 mM TPTZ in 40 mM HCl, and 20 mM FeCl$_3$, in a ratio of 10:1:1 $v/v/v$; respectively. TPTZ was then mixed with 10 µL of the sample in a 96-well plate ($n = 6$) and incubated at room temperature for 30 min in the dark. The resulting blue color was measured using a microplate reader FluoStar Omega (Ortenberg, Germany). The ability of the prepared nanoparticles to reduce ferric ions was expressed as a µM Trolox equivalent (TE)/mg sample using the
linear regression equation extracted from the linear dose-response curve of Trolox. Data are represented as means ± standard deviation (SD).

2.2.5. In Vitro Cell Viability Assay

Cell Culture

Breast adenocarcinoma cells (MCF-7) and lung cancer cells (A-549) were obtained from the American Type Culture Collection (University Boulevard, Manassas, VA, USA) and maintained in DMEM medium supplemented with streptomycin (100 mg/mL), penicillin (100 units/mL), and 10% heat-inactivated fetal bovine serum. Cells were incubated in 5% (v/v) CO$_2$ at 37 °C.

Sulfurhodamine B (SRB) Colorimetric Assay

Different concentrations of Pt (IV) ions, Pd (II) ions, Pt–Pd ions, Pt NPs, Pd NPs, and Pt–Pd NPs were added to breast adenocarcinoma cells (MCF-7) and lung cancer cells (A-549) and anticancer activities assessed using SRB assay [24–26]. Aliquots of MCF-7 and A-549 cell suspension (5 × 10$^3$ cells) were seeded in 96-well plates. Cells were incubated for 24 h at 37 °C and 7% CO$_2$ in DMEM medium. Cells were treated with aliquots of 100 µL DMEM containing containing different concentrations of Pt (IV) ions, Pd (II) ions, Pt–Pd ions, Pt NPs, Pd NPs, and Pt–Pd NPs (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, and 300 µg/mL). After 72 h, media were discarded, and 10% TCA (150 µL) was added to each well and incubated for 1 h at 4 °C then washed several times with distilled water. The SRB solution (70 µL; 0.4% w/v) was added to cells and incubated for 10 min in dark at room temperature. Finally, plates were washed with 1% acetic acid (3 ×) and allowed to dry overnight. TRIS (10 mM, 150 µL) was added to dissolve the protein-bound SRB stain and absorbance measured at 540 nm (FLUOstar Omega, Ortenberg, Germany). The IC$_{50}$ (in µg/mL) was computed from concentration-response curves by Sigma Plot software, version 12.0 (System Software, San Jose, CA, USA), using an E-max model equation. All experiments were conducted in triplicates, and data are demonstrated as mean ± standard deviation.

2.2.6. Computational Studies

Based on the anticancer activities obtained from the in vitro studies, molecular modeling studies were performed to gain an insight into the mechanistic actions of the prepared biogenic nanoparticles as anticancer agents. Active metals and metal complexes have been widely reported to inhibit several significant enzymes, including thioredoxin reductase (TrxR), cysteine proteinases, kinases, and glutathione transferase, which made them beneficial for cancer treatment [27]. The expression of proteinases in many cancer types is significantly high. Thus they represent vital targets for cancer therapy [28]. Hence, cysteine proteinase was selected as a target for the biogenic nanoparticles molecular docking studies, where its crystal structure was downloaded from pdb; code: 1CV8 [29]. The moderate antioxidant activity of the metal NPs were further investigated by molecular modeling. The crystal structure of superoxide dismutase complexed with Mn$^{2+}$ was downloaded from pdb; code: 6DQY. Minimization and docking procedures were carried out using MOE v.2010, together with dynamic simulations and both 2D and 3D resulted from interactions visualization. Hydrogens were added to downloaded proteins, and “automatically connect and type” was applied for all atoms and bonds. The receptor was selected, and fixing potential was carried out. Then, the sequential unneeded chains and ligands were deleted while pocket and complexed ligands were identified. Although the interaction between nanoparticles and enzyme proteins still lacks the adequate forcefield that could capture such binding, we tried to build a simple model of the three prepared metal nanoparticles (Pd NPs, Pt NPs and Pd-Pt NPs) following similar procedures reported in the literature [30]. The structures of the metals were drawn using the program builder, automatic connect, and type was applied. The dynamic simulation was built using start point zero-till 250 checkpoints, velocity applied, and time 0.5. Only one timing was applied for simulations (0.5 s) as a moderate choice for
the simple model. Then, the forcefield applied was set as Rule; Empirical forcefield type, charges were fixed, and the solvent was set as a water droplet to mimic the deionized water previously used in lab work. Solvent molecules were automatically calculated for each nanoparticle type. The protocol used was NPA (Nose–Poincare–Andersen–Hamiltonian equations of motion), where the radius at equilibrium was set to be 11.25, 10.15 and 16.75 nm, respectively, for Pd NPs, Pt NPs and Pd-Pt NPs. Only the equilibrium state was selected out of the produced 250 dynamic conformations for further docking studies to facilitate the visualization of the possible ligand–enzyme interaction at the most stable–least energy state. Enzyme proteins were not subjected to dynamic simulations since the study was based on metal–biomolecule interactions and not on large ligands nor protein–protein interactions; hence, the enzymes remained in fixed constraints. Docking was then computed using placement: Alpha Triangle and rescoring 1: London dG with None refinement, None rescoring 2, and retaining 10 scores.

3. Results and Discussion

3.1. Ultraviolet–Visible (UV–Vis) Spectroscopy

The bioreduction of Pt(IV) chloride, Pd(II) acetate, and Pt–Pd salt solutions to biogenic Pt NPs, Pd NPs, and Pt–Pd NPs mediated by \textit{P. harmala} seed alkaloid fraction was tracked visually and using UV–Vis spectroscopy. Initially, the formation of the nanoparticles was confirmed qualitatively by the gradual color change from pale yellow into black, brown, and dark brown colors in the case of Pt NPs, Pd NPs, and Pt–Pd NPs, respectively. The formation of the greenly synthesized NPs was further confirmed by UV–Vis spectroscopy (Figure 1). Significant surface plasmon resonance peaks were observed at 269 and 279 nm for Pt NPs and Pd NPs, respectively. These findings indicated the bioreduction of Pt (IV) and Pd (II) salt solutions into Pt NPs and Pd NPs as reported previously [31–33]. The observed absorbance by the Pt–Pd NPs was double that of either individual Pt NPs or Pd NPs.

![Figure 1. Ultraviolet–visible (UV–Vis) spectra of 0.9 mM Pt NPs, Pd NPs, and Pt–Pd NPs in deionized water synthesized using \textit{P. harmala} seed alkaloid fraction.](image)

3.2. Transmission Electron Microscopy (TEM) Analysis and $\zeta$-Potential

Transmission electron microscopy (TEM) analysis was used to determine the particle morphology diameter of the greenly synthesized nanoparticles. As depicted in Figure 2A–C, the particles showed spherical shapes with smooth margins. The mean average diameters of the greenly synthesized Pt NPs, Pd NPs, and Pt–Pd NPs were determined using the image processing program Image J (NIH, USA) and were found to be 20.3 ± 1.9, 22.5 ± 5.7, and 33.5 ± 5.4 nm, respectively. These values lie within the range of the nanoparticles previously reported to passively accumulate into the permeable vasculature of tumor cells via the enhanced permeability and retention (EPR) effect [34–36].
The ζ-potential of the biogenic Pt NPs, Pd NPs, and Pt–Pd NPs was investigated using laser Doppler velocimetry and demonstrated an outstanding negative surface charge of $-11.2 \pm 0.5$, $-9.7 \pm 1.2$, and $-12.7 \pm 2.1$ mV. The negative charge of nanoparticles’ surface prevents particle aggregation.

3.3. X-ray Diffraction (XRD)

Figure 3 demonstrates the XRD pattern of the greenly synthesized Pt NPs, Pd NPs, and Pt–Pd NPs. Three major diffraction peaks were observed at about $2\theta = 38.06^\circ$, $48.08^\circ$ and $68.24^\circ$ for Pt NPs and $2\theta = 39.7^\circ$, $48.1^\circ$, $68.4^\circ$ for Pd NPs. These values correspond to the planes (111), (200), and (220) for the face-centered cubic Pt and Pd. The Pt–Pd NPs demonstrated the presence of (111), (200), and (220) peaks, with their corresponding $2\theta$ slightly shifted toward higher values. The XRD data agreed with the previously reported findings for Pt and Pd NPs [16,31,37,38].

3.4. Fourier Transform Infrared (FTIR) Spectroscopy and Thermal Gravimetric Analysis (TGA) Analyses

The FTIR spectra of Pt NPs and Pd NPs were found to be similar to that of the Pt–Pd NPs. Thus, the FT-IR spectra of *P. harmala* seed alkaloid fraction and Pt–Pd NPs were compared (Figure 4). Four major characteristic peaks for *P. harmala* seed alkaloid fraction, were observed at 3438.6 cm$^{-1}$ (–OH stretching), 1602.6 cm$^{-1}$ (C=O asymmetry stretching), 1430.9 cm$^{-1}$ (O–H bending) and 1047.2 cm$^{-1}$ (C–O stretching). The presence of three characteristic peaks of *P. harmala* seed alkaloid fraction in the FTIR spectrum of Pt–Pd nanoparticles may suggest that molecules in the seed extract coated the nanoparticles. However, the peaks’ intensities at 3438.6 cm$^{-1}$ (–OH stretching), 1430.9 cm$^{-1}$ (O–H bending), and 1430.9 cm$^{-1}$ (C–O stretching) were significantly reduced, indicating a lower concentration of *P. harmala* seed alkaloid fraction, possibly indicating the rearrangement and deprotonation of these groups which may be involved in the bioreduction and stabilization processes [34]. Additionally, the peak at 1602.6 cm$^{-1}$ (attributed to the carbonyl group) was significantly diminished in the FTIR spectrum of Pt–Pd NPs, which may suggest conjugation of nanoparticles with the *P. harmala* seed alkaloid fraction via carbonyl groups [16–18]. The content of the bioorganic material surrounding the NPs was estimated using thermal gravimetric analysis (TGA) analysis.
Figure 3. X-ray diffraction (XRD) profiles of (A) Pt NPs, (B) Pd NPs, and (C) Pt–Pd NPs greenly synthesized by *P. harmala* seed alkaloid fraction.

Figure 4. Fourier transform infrared (FTIR) spectra of *P. harmala* seed alkaloid fraction and Pt–Pd NPs.

The TGA thermogram of Pt–Pd NPs is illustrated in Figure 5 (TGA thermograms of Pt NPs and Pd NPs were found to be similar to that of the Pt–Pd NPs). A constant weight loss of the Pt–Pd NPs was detected from 20 to 400 °C. The thermal decomposition of the bioorganic compounds of *P. harmala* seed alkaloid fraction coating the Pt–Pd NPs reduced their weight by 44.24%.
3.5. FRAP Assay

The antioxidant activities of the prepared metallic nanoparticles compared to harmala alkaloid fraction (adjusted to the content of the organic material in the NPs, 44.24%) were assessed by FRAP assay. The results were expressed with reference to Trolox standard as µM Trolox equivalent (TE)/mg samples. The FRAP values of harmala alkaloid fraction, Pt NPs, Pd NPs, and Pt–Pd NPs were 33.91 ± 5.82, 277.3 ± 13.5, 167.6 ± 4.8, and 843 ± 60 µM TE/mg NPs, respectively, (Figure 6). Notably, Pt (IV), Pd (II), and Pt–Pd ions showed undetectable antioxidant activities. These findings showed that the metal ions’ bioreduction using \textit{P. harmala} seed alkaloid fraction has almost quadrupled their antioxidant activities. Our findings are in good agreement with previous studies that reported remarkable antioxidant activity of the Pt–Pd NPs [39].

3.6. In Vitro Cell Viability Assay

The cytotoxic activities of Pt NPs, Pd NPs, and Pt–Pd NPs compared to the individual metals ions were evaluated on lung cancer cells (A549) and breast adenocarcinoma cells (MCF-7) employing SRB assay. The green synthesized metallic nanoparticles exhibited significant in vitro cytotoxic activities compared to the individual metal ions. The cytotoxic
activities (IC\textsubscript{50} in µg/mL, computed by Sigma plot) of the biogenic metallic nanoparticles against both cell lines are presented in Table 1 and Figure S1. The synthesized Pt–Pd NPs revealed the highest cytotoxic activity against A549 and MCF-7 cells, IC\textsubscript{50} of 8.8 and 3.6 µg/mL, respectively; compared to either Pt NPs (IC\textsubscript{50} of 10.9 and 6.7 µg/mL, respectively) and Pd NPs (IC\textsubscript{50} of 31 and 10.8 µg/mL, respectively). This is attributed to the synergistic effect of both transition metals. The synthesized Pt NPs showed higher cytotoxic effects against both A549 and MCF-7 cancer cell lines than Pd NPs. Previous studies showed that the biogenic Pt NPs exert their cytotoxic effects via the induction of apoptosis and cell cycle arrest [40]. Additionally, Pt complexes are used in the design of many platinum-based anticancer drugs, some of which are U. S. Food and Drug Administration (FDA) approved (such as cisplatin, carboplatin, and oxaliplatin); others are still not granted FDA approval (such as nedaplatin) [41]. Moreover, the synthesized Pt–Pd NPs showed higher cytotoxic activity against A549 and MCF-7 cells, when compared to the second-generation platinum-based drug carboplatin (IC\textsubscript{50} of 23 and 9.5 µg/mL, respectively) [25]. Synthetic platinum-based drugs possess many adverse effects ranging from nephrotoxicity to multi-drug resistance, which hinder their clinical applications [42,43]. On the other hand, the green synthesized NNPs are promising candidates towards the design of safer and effective antitumor agents [44]. Some studies reported the safety and biocompatibility of NNPs capped with plant extracts compared to platinum-based anticancer drugs such as cisplatin, carboplatin, and oxaliplatin [4,5]. Pd NPs produced using Agaricus bisporus (mushroom) fungi were found to be biocompatible with red blood cells [45]. Also, Pt NPs synthesized utilizing the aqueous extract of the Indian brown seaweed Padina gymnospora were found to be biocompatible to red blood cells with no detected hemolytic activity [46]. Pt NPs produced employing leaf extract of Maytenus royleanus, were reported to exhibit anticancer activity against A549 cancer cells and low cytotoxicity against normal cells [47]. These findings will revive interest in platinum-based cancer therapeutics.

Table 1. In vitro cytotoxic activities of \textit{P. harmala} seed alkaloid fraction mediated Pt NPs, Pd NPs, and Pt–Pd NPs compared to their individual metal ions against A549 lung cancer cells and breast adenocarcinoma cells (MCF-7).

| Cells | In Vitro Cytotoxic Activity (IC\textsubscript{50} in µg/mL) |
|-------|------------------------------------------------------|
|       | Pt (IV) Ions | Pd (II) Ions | Pt–Pd Ions | Pt NPs | Pd NPs | Pt–Pd NPs |
| A549  | 90.8 ± 0.54  | 91.9 ± 0.67  | 73.7 ± 0.23 | 10.9 ± 0.31 | 31 ± 0.28 | 8.8 ± 0.11 |
| MCF-7 | 29.8 ± 0.35  | 48.7 ± 0.73  | 21.4 ± 0.19 | 6.7 ± 0.44  | 10.8 ± 0.59 | 3.6 ± 0.29 |

3.7. Molecular Modeling Studies
3.7.1. Molecular Docking Using Cysteine Proteinase

The crystal structure of staphopain cysteine proteinase from \textit{Staphylococcus Aureus} V8 was downloaded from pdb; 1CV8 [29]; its active site was already defined from pdb and was selected as the pocket for interaction in the program software. The metal Au is well known for its inhibitory activity in many cancer types, especially the thiol-containing proteinases [27], thus Au was selected as a reference inhibitor in this molecular docking study and the same dynamic simulation model was applied to Au\textsuperscript{+2} for a fair comparison to the candidate nanoparticles. After preparing the enzyme to be ready for docking, the dynamic nanoparticle models were set using MOEv.2010 and the resulted models were reference (Au\textsuperscript{+2} NPs) and tested metals (Pd\textsuperscript{0} NPs, Pt\textsuperscript{+2} NPs, and Pd\textsuperscript{0}–Pt\textsuperscript{+2} mixture). Dynamic models were based on most of the nanoparticles in the reduced forms and only a small percentage in charged forms except for the Pt model where the charged forms constituted most of the model. Molecular docking studies were also performed between the prepared enzymes and each conformer obtained at equilibrium from the prepared four models using MOEv.2010. The results are presented in Table 2. The color map of interactions is supplied in the Supplementary Material (Figure S2) together with the 2D interaction of each tested active metal without the external water surface of the designed nanoparticle (Figure S3).
Au$^{+2}$NP displayed a score of interaction energy of the best-docked pose = $-17.07 \text{kcal/mol}$ showing ligand exposure to the key amino acid Arg 86, as shown in Figure 7. Although Pd$^{0}$NP showed a higher score than reference = $-22.4 \text{kcal/mol}$, the interaction mode was contrarily presenting ligand exposure to Arg 113. On the other hand, Pt$^{+2}$NP showed both higher score = $-26.19 \text{kcal/mol}$ and enhanced mode of interaction with two amino acids ligand exposure; Asn 85 and Arg 86, thus being more embedded in the pocket of the active site as shown in Figure 7. Finally, the Pd$^{0}$-Pt$^{+2}$ mixture displayed the highest score = $-30.29 \text{kcal/mol}$ and enhanced interaction similar to that of Pt$^{+2}$NP where Pd$^{0}$ was closer to Asn 85 and Pt$^{+2}$ distanced from Pd$^{0}$ by 6.75 Å, was closer to Arg 86. These findings correlated to those obtained from the in vitro cell viability assays conducted on both cancer cell lines. Thus, in vitro cysteine proteinase inhibition assay may be performed in the future to evaluate the anticancer activities of platinum-based drugs.

Table 2. Molecular docking of the four dynamic metal models against cysteine proteinase enzyme.

| Metal Ligand                  | Score (kcal/mol) | Type of Interaction | Key Amino Acids |
|-------------------------------|------------------|---------------------|-----------------|
| Au$^{+2}$NP (Reference-inhibitor) | $-17.07$         | Ligand exposure     | Arg 86          |
| Pd$^{0}$NP                    | $-22.4$          | Ligand exposure     | Arg 113         |
| Pt$^{+2}$NP                   | $-26.19$         | Ligand exposure     | Asn 85, Arg 86  |
| Pd$^{0}$-Pt$^{+2}$NP          | $-30.29$         | Ligand exposure     | Asn 85, Arg 86  |

Figure 7. Left image: 3D interaction-ligand exposure between Au$^{+2}$NP and key amino acids of cysteine proteinase. Right image: 3D interaction-ligand exposure between Pt$^{+2}$NP and key amino acids of cysteine proteinase (both generated by MOE v.2010). The ribbon shape represents the receptor (cysteine proteinase), the lined molecules represents the model surface of the nanoparticles and the solid ball in the middle represents the active metal.

3.7.2. Molecular Docking Using Superoxide Dismutase

Superoxide dismutase (SOD) protects organisms against potentially damaging oxygen radicals by catalyzing the disproportionation of superoxide to oxygen and hydrogen peroxide [48]. Hence, SOD was selected to explore the prepared biogenic metal nanoparticles effect compared to Mn$^{+2}$ complexed with SOD as a reference. The crystal structure of superoxide dismutase from *Trichoderma reesei* (pdb: 6DQY) was downloaded from the protein data bank. Four dynamic simulated models were built; reference agonist Mn$^{+2}$NPs, Pd$^{0}$NPs, Pt$^{+2}$NPs, and Pd$^{0}$-Pt$^{+2}$ mixture using MOE v.20120. Alpha triangle docking was applied between the prepared superoxide dismutase, and the four built dynamic models. The results (Table 3) show that the reference agonist Mn$^{+2}$NPs with interaction score = $-12.37 \text{kcal/mol}$ was embedded in the active pocket site made out of His 30, His 78, Trp 131, Gln 149, Asp 163 and His 167 amino acids without direct ligand exposure as shown...
in Figure 8. The Pd$^0$-Pt$^{+2}$ mixture NPs were similar to that of the reference, only embedded within the same pocket with a score = $-10.26$ kcal/mol where Pt$^{+2}$ was much closer to the pocket than Pd$^0$ that distanced from Pt$^{+2}$ by 6.75 Å. As for Pd$^0$ NPs and Pt$^{+2}$ NPs, they displayed different interaction than both reference and the mixture, showing ligand exposure to Ile 207 with docking scores = $-11.70$ and $-13.09$ kcal/mol, respectively. The 2D interaction modes of Pd$^0$NPs and Pt$^{+2}$NPs are presented in Figure S4. These results also correlated with that of the FRAP assay where the mixture’s antioxidant activity was the best compared to individual NPs.

Table 3. Molecular docking of the four dynamic metal models against superoxide dismutase enzyme.

| Metal Ligand      | Score (kcal/mol) | Type of Interaction | Key Amino Acids                      |
|-------------------|------------------|---------------------|--------------------------------------|
| Mn$^{+2}$NPs      | $-12.37$         | Hydrophobic Pocket  | His 30, His 78, Trp 131, Gln 149, Asp 163 and His 167 |
| Pd$^0$NPs        | $-11.70$         | Ligand exposure     | Ile 207                              |
| Pt$^{+2}$NPs      | $-13.09$         | Ligand exposure     | Ile 207                              |
| Pd$^0$-Pt$^{+2}$NPs | $-10.26$       | Hydrophobic Pocket  | His 30, His 78, Trp 131, Gln 149, Asp 163 and His 167 |

Figure 8. Left image: 3D visualization of Mn$^{+2}$NP inside active site pocket of superoxide dismutase. Right image: 3D visualization of Pd$^0$-Pt$^{+2}$ NPs mixture inside the pocket generated by MOEv.2010. The ribbon shape represented the receptor (superoxide dismutase), the lined molecules represented the model surface of the nanoparticles and the solid ball in middle represented the active metal.

4. Conclusions

This work reports a simple environmentally friendly method for the green synthesis of Pt NPs, Pd NPs, and Pt–Pd NPs employing alkaloid-rich *Peganum harmala* seed extract fraction. The average diameters of the green synthesized spherical Pt NPs, Pd NPs, and Pt–Pd NPs were 20.3 $\pm$ 1.9, 22.5 $\pm$ 5.7, and 33.5 $\pm$ 5.4 nm, respectively. The $\zeta$-potential of the Pt NPs, Pd NPs, and Pt–Pd NPs were $-11.2 \pm 0.5$, $-9.7 \pm 1.2$, and $-12.7 \pm 2.1$ mV, respectively. The metal nanoparticles’ bioreduction was confirmed by UV–vis spectroscopy, XRD, FTIR, and their organic contents determined by TGA analysis. The Pt–Pd NPs showed more pronounced antioxidant activity of $843 \pm 60 \mu$M TE/mg NPs compared to the individual Pt NPs ($277.3 \pm 13.5 \mu$M TE/mg NPs) and Pd NPs ($167.6 \pm 4.8 \mu$M TE/mg NPs). Furthermore, the Pt–Pd NPs exhibited significant cytotoxic activities against lung cancer and breast adenocarcinoma cells with IC$_{50}$ of 8.8 and 3.6 $\mu$g/mL, respectively, compared to the individual Pt NPs (IC$_{50}$ of 10.9 and 6.7 $\mu$g/mL, respectively) and Pd NPs (IC$_{50}$ of 31 and 10.8 $\mu$g/mL, respectively) and compared to carboplatin (IC$_{50}$ of 23 and 9.5 $\mu$g/mL, respectively). The in silico studies were carried out using MOEv.2010, where dynamic simulation models were built up to mimic the prepared nanoparticles’ kinetics. Docking studies showed that Pt and Pd metals exhibited promising activity against the
selected cysteine proteinase enzyme and less activity against superoxide dismutase as compared to other metal references under the same conditions. Docking results proposed a possible mechanism of action of the antitumor activity of the biogenic metals, which is supported by the in vitro assay results, via inhibition of a critical proteolytic enzyme. In conclusion, Pt–Pd NPs capped with biological entities from alkaloid-rich harmala seed extract could be used as promising safe antitumor agents. This study will revive interest in Pt-based cancer therapeutics synthesized by green approaches as potentially effective and safe cancer therapy candidates.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nano11040965/s1, Figure S1: Evaluating the cytotoxicity of Pt NPs, Pd NPs, and Pt–Pd NPs compared to the individual metals ions at various concentrations ranging from 0.01 to 300 µg/mL using sulforhodamine B (SRB) assay in (A) lung cancer (A549) and (B) breast adenocarcinoma (MCF-7) cells. An overall statistically significant decrease in cell viability was observed with the nanoparticles compared to individual metal ions (p < 0.05). Untreated cells were used as negative control and considered as 100%. All experiments were carried out in triplicates, and the mean values were calculated. Error bars represent ± standard deviation; Figure S2: Color map of interaction modes between ligands and enzymes provided by MOE v. 2010; Figure S3: 2D interaction-ligand exposure between the four metal dynamic designed nanoparticles (Au²⁺ NPs and tested metals; Pd⁰ NPs, Pt²⁺ NPs and Pd⁰-Pt²⁺ mixture NPs) and key amino acids of cysteine proteinase displayed by MOE v.2010 and Figure S4: 2D interaction-ligand exposure between Pd⁰ NPs and Pt²⁺ NPs designed dynamic models and key amino acids of superoxide dismutase displayed by MOE v.2010.

Author Contributions: Conceptualization, S.A.F., U.B. and H.M.E.-S.A.; methodology, S.A.F., I.M.F. and B.M.S.; data curation, S.A.F., B.M.S., M.Y.I. and I.M.F.; writing—original draft preparation, S.A.F.; writing—review and editing, S.A.F., M.Y.I., I.M.F., U.B. and H.M.E.-S.A.; supervision, U.B. and H.M.E.-S.A.; project administration, U.B. and H.M.E.-S.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work has been funded by a grant from the American University in Cairo to Hassan Azzazy.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fahmy, S.A.; Mamdouh, W. Garlic oil–loaded PLGA nanoparticles with controllable size and shape and enhanced antibacterial activities. J. Appl. Polym. Sci. 2018, 135, 46133. [CrossRef]
2. El-Shafie, S.; Fahmy, S.A.; Ziko, L.; Elzahed, N.; Shoeib, T.; Kakarougkas, A. Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells. Pharmaceuticals 2020, 12, 863. [CrossRef] [PubMed]
3. Fahmy, S.A.; Alawak, M.; Brüller, J.; Bakowsky, U.; El-Sayed, M.M.H. Nano-enabled Bioseparations: Current developments and future prospects. BioMed. Res. Int. J. 2019, 2019, 1–15. [CrossRef] [PubMed]
4. Fahmy, S.A.; Preis, E.; Bakowsky, U.; Azzazy, H.M.E.-S. Platinum Nanoparticles: Green Synthesis and Biomedical Applications. Molecules 2020, 25, 4981. [CrossRef]
5. Fahmy, S.A.; Preis, E.; Bakowsky, U.; Azzazy, H.M.E.-S. Palladium Nanoparticles Fabricated by Green Chemistry: Promising Chemotherapeutic, Antioxidant and Antimicrobial Agents. Materials 2020, 13, 3661. [CrossRef]
6. Saldan, I.; Semenyuk, Y.; Marchuk, I.; Reshetnyak, O. Chemical synthesis and application of palladium nanoparticles. J. Mater. Sci. 2015, 50, 2337–2354. [CrossRef]
7. Liu, Y.; Wang, D.-D.; Zhao, L.; Lin, M.; Sun, H.-Z.; Sun, H.-C.; Yang, B. Polypyrrole-coated flower-like Pd nanoparticles (Pd NPs@Ppy) with enhanced stability and heat conversion efficiency for cancer photothermal therapy. RSC Adv. 2016, 6, 15854–15860. [CrossRef]
8. Azizi, S.; Mahdavi Shahri, M.; Rahman, H.S.; Rahim, R.A.; Raseedi, A.; Mohamad, R. Green synthesis palladium nanoparticles mediated by white tea (Camellia sinensis) extract with antioxidant, antibacterial, and antiproliferative activities toward the human leukemia (MOLT-4) cell line. Int. J. Nanomed. 2017, 12, 8841–8853. [CrossRef]
9. Ghosh, S.; Nittavare, R.; Dewle, A.; Tomar, G.B.; Chippalkatti, R.; More, P.; Chopade, B.A. Novel platinum–palladium bimetallic nanoparticles synthesized by Dioscorea bulbifera: Anticancer and antioxidant activities. Int. J. Nanomed. 2015, 10, 7477–7490. [CrossRef]
10. Nugroho, F.A.A.; Iandolo, B.; Wagner, J.B.; Langhammer, C. Bottom-up nanofabrication of supported noble metal alloy nanoparticle arrays for plasmonics. ACS Nano 2016, 10, 2871–2879. [CrossRef]
11. Jeyaraj, M.; Gurunathan, S.; Qasim, M.; Kang, M.-H.; Kim, J.-H. A Comprehensive Review on the Synthesis, Characterization, and Biomedical Application of Platinum Nanoparticles. J. Nanomater. 2019, 9, 1719. [CrossRef]
12. Puja, P.; Kumar, P. A perspective on biogenic synthesis of platinum nanoparticles and their biomedical applications. *Spectrochim. Acta A* 2019, 211, 94–99. [CrossRef]

13. Mittal, A.K.; Chisti, Y.; Banerjee, U.C. Synthesis of metallic nanoparticles using plant extracts. *Biotechnol. Adv.* 2013, 31, 346–356. [CrossRef]

14. Thakker, K.N.; Mhatre, S.S.; Parikh, R.Y. Biological synthesis of metallic nanoparticles. *Nanomed. J.* 2010, 6, 257–262. [CrossRef]

15. Salem, S.S.; Fouda, A. Green Synthesis of Metallic Nanoparticles and Their Prospective Biotechnological Applications: An Overview. *Biol. Trace Elem. Res.* 2021, 199, 344–370. [CrossRef]

16. Ayguna, A.; Gülbağcaya, F.; Ozerb, L.Y.; Ustaoglu, B.; Altunoglu, Y.C.; Baloglu, M.C.; Atalard, M.N.; Almae, M.H.; Sena, F. Biogenic platinum nanoparticles using black cumin seed and their potential usage as antimicrobial and anticancer agent. *J. Pharm. Biomed. Anal.* 2020, 179, 119261. [CrossRef]

17. Shaheen, H.A.; Issa, M.Y. In vitro and in vivo activity of *Peganum harmala* L. alkaloids against phytopathogenic bacteria. *Sci. Hortic.* 2020, 264, 108940. [CrossRef]

18. Apostolico, I.; Aliberti, L.; Caputo, L.; De Feo, V.; Fratianni, F.; Nazzaro, F.; Souza, L.F.; Khadhr, M. Chemical Composition, Antibacterial and Phytotoxic Activities of *Peganum harmala* Seed Essential Oils from Five Different Localities in Northern Africa. *Molecules* 2016, 21, 1235. [CrossRef]

19. Herraz, T.; González, D.; Ancín-Azpilicueta, C.; Arán, V.; Guillén, H. β-Caroline alkaloids in *Peganum harmala* and inhibition of human monoamine oxidase (MAO). *Food Chem. Toxicol.* 2010, 48, 839–845. [CrossRef]

20. Alomari, A.A.; Fares, K.E.K.; Moustafa, N.E. Green synthesis of assembled silver nanoparticles in nano capsules of *Peganum harmala* L. leaf extract. Antibacterial activity and conjugate investigation. *Cog. Chem.* 2018, 4, 1532374. [CrossRef]

21. Moustafa, N.E.; Alomari, A.A. Green synthesis and bactericidal activities of isotropic and anisotropic spherical gold nanoparticles produced using *Peganum harmala* L. leaf and seed extracts. *Biotecnol. Appl. Biochem.* 2019, 66, 664–672. [CrossRef]

22. Mehar, S.; Khoso, S.; Qin, W.; Anam, I.; Iqbal, A.; Iqbal, K. Green Synthesis of Zinc Oxide Nanoparticles from *Peganum harmala*, and its biological potential against bacteria. *Front. Nanosci. Nanotech.* 2019, 6, 1–5. [CrossRef]

23. Benzie, I.F.; Strain, J.J. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. *Anal. Biochem.* 1996, 239, 70–76. [CrossRef]

24. Fahmy, S.A.; Ponte, F.; Abd El-Rahman, M.K.; Russo, N.; Sicilia, E.; Shoeib, T. Investigation of the host-guest complexation between 4-sulfolinic[4]arene and nedaplatin for potential use in drug delivery. *Spectrochim. Acta Part A Mol. Biomol. Spectros.* 2018, 193, 528–536. [CrossRef]

25. Fahmy, S.A.; Ponte, F.; Sicilia, E.; Azzazy, H.M.E.-S. Experimental and Computational Investigations of Carboplatin Supramolecular Complexes. *ACS Omega* 2020, 5, 31456–31466. [CrossRef]

26. Fahmy, S.A.; Ponte, F.; Fawzy, I.M.; Sicilia, E.; Bakowsky, U.; Azzazy, H.-S. Host-Guest Complexation of Oxaliplatin and Para-Sulfonatocalix[n]Arenes for Potential Use in Cancer Therapy. *Molecules* 2020, 25, 5926. [CrossRef]

27. Kilpin, K.J.; Dyson, P.J. Enzyme inhibition by metal complexes: Concepts, strategies and applications. *Chem. Sci.* 2013, 4, 1410–1419. [CrossRef]

28. Rath, B.; Klameth, L.; Plangger, A.; Hochmair, M.; Ul sperger, E.; Huk, I.; Zei llinger, R.; Hamilton, G. Expression of proteolytic enzymes by small cell lung cancer circulating tumor cell lines. *Cancers* 2019, 11, 114. [CrossRef]

29. Hofmann, B.; Schumborg, D.; Hecht, H.J. Crystal structure of a thiol proteinase from Staphylococcus aureus V-8 in the E-64 inhibitor complex. *Acta Crystallogr.* 1993, 49, 102. [CrossRef]

30. Radic, S.L. Biophysical Interaction between Nanoparticles and Biomolecules. Clemson–University-Libraries. *All Diss.* 2015, 1517. Available online: https://tigerprints.clemson.edu/all_dissertations/1517 (accessed on 28 March 2021).

31. Gurunathan, S.; Kang, M.H.; Jeyaraj, M.; Kim, J.H. Platinum Nanoparticles Enhance Exosome Release in Human Lung Epithelial Adenocarcinoma Cancer Cells (A549): Oxidative Stress and the Ceramide Pathway are Key Players. *Int. J. Nanomed.* 2021, 16, 515–538. [CrossRef] [PubMed]

32. Yang, C.; Wang, M.; Zhou, J.; Chi, Q. Bio-synthesis of peppermint leaf extract polyphenols capped nano-platinum and their in-vitro cytotoxicity towards colon cancer cell lines (HCT 116). *Mater. Sci. Eng. C* 2017, 77, 1012–1016. [CrossRef] [PubMed]

33. Tahir, K.; Nazir, S.; Ahmad, A.; Li, B.; Khan, A.U.; Khan, Z.U.H.; Khan, F.U.; Khan, Q.U.; Khan, A.; Rahman, A.U. Facile and green synthesis of phytochemicals capped platinum nanoparticles and in vitro their superior antibacterial activity. *J. Photochem. Photobiol. B Biol.* 2017, 166, 246–251. [CrossRef] [PubMed]

34. Amin, M.; Hameed, S.; Ali, A.; Anwar, F.; Shahid, S.A.; Shakir, I.; Yaqoob, A.; Hasan, S.; Khan, S.A.; Sajjad-ur-Rahman. Green synthesis of silver nanoparticles: Structural features and in vivo and in vitro therapeutic effects against *Helicobacter pylori* induced gastritis. *Bioinorg. Chem. Appl.* 2014, 2014, 135824. [CrossRef]

35. Imran, M.; Shah, M.R.; Ullah, F.; Ullah, S.; Sadiq, A.; Ali, I.; Ahmed, F.; Nawaz, W. Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of Cefixime. *Artif. Cells Nanomed. Biotechnol.* 2017, 45, 1440–1451. [CrossRef]

36. Cho, K.; Wang, X.; Nie, S.; Shin, D.M. Therapeutic Nanoparticles for Drug Delivery in Cancer. *Clin. Cancer Res.* 2008, 14, 1310–1316. [CrossRef]

37. Sahin, B.; Aygün, A.; Gündüz, H.; Sahin, K.; Demir, E.; Akocak, S.; Sen, F. Cytotoxic effects of platinum nanoparticles obtained from pomegranate extract by the green synthesis method on the MCF-7 cell line. *Colloids Surf. B Biointerfaces* 2018, 163, 119–124. [CrossRef]
38. Rabiee, N.; Bagherzadeh, M.; Kiani, M.; Ghadiri, A.M. Rosmarinus officinalis directed palladium nanoparticle synthesis: Investigation of potential antibacterial, antifungal and Mizoroki-Heck catalytic activities. *Adv. Powder Technol.* 2020, 15, 3983–3999. [CrossRef]

39. Shibuya, S.; Ozawa, Y.; Watanabe, K.; Izuo, N.; Toda, T.; Yokote, K.; Shimizu, T. Palladium and platinum nanoparticles attenuate aging-like skin atrophy via antioxidant activity in mice. *PLoS ONE* 2014, 9, e109288. [CrossRef]

40. Bendale, Y.; Bendale, V.; Paul, S. Evaluation of cytotoxic activity of platinum nanoparticles against normal and cancer cells and its anticancer potential through induction of apoptosis. *Integr. Med. Res.* 2017, 6, 141–148. [CrossRef]

41. Wexselblatt, E.; Yavin, E.; Gibson, D. Cellular interactions of platinum drugs. *Inorg. Chim. Acta* 2012, 393, 75–83. [CrossRef]

42. Kapdi, R.; Fairlamb, I.J.S. Anti-cancer palladium complexes: A focus on PdX2L2, palladacycles and related complexes. *Chem. Soc. Rev.* 2014, 43, 4751–4777. [CrossRef]

43. Fahmy, S.A.; Brüßler, J.; Alawak, M.; El-Sayed, M.M.H.; Bakowsky, U.; Shoeib, T. Chemotherapy Based on Supramolecular Chemistry: A Promising Strategy in Cancer Therapy. *Pharmaceutics* 2019, 11, 292. [CrossRef]

44. Zeng, X.; Sun, J.; Li, S.; Shi, J.; Gao, H.; Leong, W.S.; Wu, Y.; Li, M.; Liu, C.; Li, P.; et al. Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agent. *Nat. Commun.* 2020, 11, 1–12. [CrossRef]

45. Mohana, S.; Sumathi, S. Multi-Functional Biological Effects of Palladium Nanoparticles Synthesized Using Agaricus bisporus. *J. Clust Sci.* 2020, 31, 391–400. [CrossRef]

46. Ramkumar, V.S.; Pugazhendhi, A.; Prakash, S.; Ahila, N.K.; Vinoj, G.; Selvam, S.; Kumar, G.; Kannapiran, E.; Rajendran, R.B. Synthesis of platinum nanoparticles using seaweed Padina gymnospora and their catalytic activity as PVP/PtNPs nanocomposite towards biological applications. *Biomed. Pharmacother.* 2017, 92, 479–490. [CrossRef]

47. Ullah, S.; Ahmad, A.; Wang, A.; Raza, M.; Jan, A.U.; Tahir, K.; Rahman, A.U.; Qipeng, Y. Bio-fabrication of catalytic platinum nanoparticles and their in vitro efficacy against lungs cancer cells line (A549). *J. Photochem. Photobiol. B Biol.* 2017, 173, 368–375. [CrossRef]

48. Borgstahl, G.E.; Pokross, M.; Chehab, R.; Sekher, A.; Snell, E.H. Cryo-trapping the six-coordinate, distorted-octahedral active site of manganese superoxide dismutase. *J. Mol. Biol.* 2000, 296, 951–959. [CrossRef]